Breast and ovarian cancer vaccines
The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
1. A composition comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 39 or a fragment thereof, wherein SEQ ID NO: 39 or the fragment thereof is a fusion protein, and wherein SEQ ID NO: 39 or the fragment thereof comprise a plurality of epitopes, wherein the plurality of epitopes comprises all the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 25, and SEQ ID NO: 32.
2. The composition of claim 1 , wherein the amino acid sequence has at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 39 or the fragment thereof.
3. The composition of claim 1 , wherein the amino acid sequence consists of the amino acid sequence of SEQ ID NO: 39.
4. The composition of claim 1 , wherein the composition further comprises a pharmaceutical carrier, an adjuvant, or a combination thereof.
5. The composition of claim 4 , wherein the adjuvant is GM-CSF.
6. The composition of claim 1 , wherein the plurality of epitopes comprises a plurality of contiguous epitopes.
7. The composition of claim 1 , wherein the plurality of epitopes comprises one or more linkers between one or more epitopes.
8. A method of treating a breast or ovarian cancer in a subject in need thereof, the method comprising:
a) administering the composition of claim 1 to the subject; and
b) eliciting an immune response to a breast or ovarian cancer cell in the subject.
9. A method of treating a breast or ovarian cancer in a subject in need thereof, the method comprising:
a) administering the composition of claim 1 to the subject; and
b) eliminating a number of breast or ovarian cancer cells in the subject.
10. The method of claim 8 , wherein the immune response is a Type I immune response.
11. The method of claim 8 , wherein the immune response is characterized by a ratio of Type I cytokine production to Type II cytokine production that is greater than 1.
12. The method of claim 8 , wherein the immune response is characterized by a ratio of IFNg production to IL-10 production that is greater than 1.